Werewolf Therapeutics, Inc. (HOWL) has disclosed a new risk, in the Share Price & Shareholder Rights category.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Werewolf Therapeutics, Inc. faces a significant listing risk after receiving a Nasdaq deficiency notice on February 4, 2026, for failing to meet the $1.00 minimum bid price requirement. If the company does not restore compliance by August 3, 2026, by maintaining a closing bid of at least $1.00 for 10 consecutive business days, its common stock could be delisted, materially harming liquidity and capital-raising prospects.
Overall, Wall Street has a Moderate Buy consensus rating on HOWL stock based on 1 Buy.
To learn more about Werewolf Therapeutics, Inc.’s risk factors, click here.